Loading
double plasma cytokine adsorption system with sequential low-dose plasma exchang / plasma exchange / Sepsis · Interventional Study
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a recruiting clinical trial comparing a double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) to plasma exchange alone in patients with acute-on-chronic liver failure complicated by sepsis. No results are posted in this registry record; the study aims to assess 4-week and 12-week mortality, organ function scores, and cytokine adsorption efficiency. Clinicians should await completion and peer-reviewed publication before drawing clinical conclusions.
Interventional, Randomized, Parallel, Open label, Treatment purpose. Acute-On-Chronic Liver Failure, Sepsis; age from 18 Years; to 70 Years. Intervention: Double plasma cytokine adsorption system with sequential lo…. Compared with: Plasma exchange — Active Comparator. n = 192. 1 site: China.
This is a recruiting clinical trial comparing a double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) to plasma exchange alone in patients with acute-on-chronic liver failure complicated by sepsis. No results are posted in this registry record; the study aims to assess 4-week and 12-week mortality, organ function scores, and cytokine adsorption efficiency. Clinicians should await completion and peer-reviewed publication before drawing clinical conclusions.
No baseline characteristics, inclusion/exclusion criteria detail, or interim safety data are provided. Outcome data, effect sizes, and safety events are not reported in this record.
The source did not state who this applies to in practice.
This is an active clinical trial registration with no posted results; it describes a planned interventional study in a critical population with mortality as primary endpoint, but outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06562803). This is a study registration, not published results. Lead sponsor: Third Affiliated Hospital, Sun Yat-Sen University. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 192 participants (ESTIMATED). Conditions: Acute-On-Chronic Liver Failure, Sepsis. Interventions: DEVICE: double plasma cytokine adsorption system with sequential low-dose plasma exchange; OTHER: plasma exchange. Primary outcome measures: Mortality rate , 4 weeks. Brief summary: This study aims to evaluate the efficacy and safety of the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) in patients with acute-on-chronic liver failure (ACLF) complicated by sepsis. The focus is on assessing the impact of the cytokine adsorption column(CA280,Jafron Biomedical Co., Ltd., Zhuhai, China) on survival rates, inflammation markers, and organ function to determine its potential value in clinical practice. The primary research questions are: (1) Does DPCAS+LPE artificial liver therapy improve the 4-week mortality rate in ACLF patients with sepsis? (2) Does it improve the 12-week mortality rate in these patients? Additionally, the study examines the effects of this therapy on APACHE II scores, SOFA scores, vasoactive-inotropic score, MELD scores, and COSSH-ACLF II scores, as well as the cytokine adsorption efficiency of the CA280. Patients were randomly assigned to either the DPCAS+LPE group or the plasma exchange(PE) group. All patients received artificial liver therapy every other day, for a total of two sessions. Follow-up assessments were conducted before and after each therapy session, as well as at 1, 2, 3, 4, and 12 weeks.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.